Pediatric ExclusivityLike Death and Taxes?

• FDA report to Congress: January 1, 2001

  • Effectiveness of program (information about important pediatric uses for approved drugs)
  • Adequacy of incentive
  • Economic impact (e.g., consumers, taxpayers, lack of generics)
  • Suggested modifications

• Sunset: January 1, 2002

Previous slide

Next slide

Back to first slide

View graphic version